Table 3.
Risk of MACE and composite CV events in patients on GnRH antagonists compared with patients on GnRH agonists by pre-existing cardiovascular disease.
| MACE | Composite CV eventsa | |||||||
|---|---|---|---|---|---|---|---|---|
| No. of events | aHRb | (95% CI) | P value | No. of events | aHRc | (95% CI) | P value | |
| All | ||||||||
| GnRH antagonist (n = 499) | 136 | 0.97 | (0.81–1.17) | 0.7665 | 24 | 0.34 | (0.21–0.55) | <0.0001 |
| GnRH agonist (n = 15,127) | 5105 | – | 2001 | – | ||||
| Pre-existing CVDd | ||||||||
| GnRH antagonist (n = 167) | 39 | 0.67 | (0.46–0.96) | 0.0299 | 5 | 0.16 | (0.05–0.50) | 0.0017 |
| GnRH agonist (n = 3348) | 1046 | – | 462 | – | ||||
| No pre-existing CVD | ||||||||
| GnRH antagonist (n = 332) | 97 | 1.23 | (0.91–1.40) | 0.2901 | 19 | 0.44 | (0.26–0.74) | 0.0019 |
| GnRH agonist (n = 11,779) | 4059 | – | 1539 | – | ||||
aHR adjusted hazard ratio, CV cardiovascular, CVD, cardiovascular disease(s), GnRH gonadotropin-releasing hormone, MACE major adverse cardiovascular event (ischemic heart disease, stroke, congestive heart failure or all cause deaths), occurring ≥90 days after ADT initiation, whichever came first.
aComposite CV events: ischemic heart disease, stroke, congestive heart failure or CV deaths occurring ≥90 days after ADT initiation, whichever came first.
bAdjusted hazard ratios were estimated using cox model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
cAdjusted hazard ratios were estimated using the Fine and Gray competing risk model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
dPre-existing CVD: receiving cardiac therapy, diagnosis of ischemic heart diseases, stroke, or congestive heart failure 1 year before androgen deprivation therapy initiation.